Lantheus Holdings opened at $101.60, in line with its previous close of $101.60. In the last trading session, the stock traded between $101.09 and $101.80. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Lantheus Holdings is now worth
$ 337.98
Giving a profit of
$ 237.98 (237.98%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.34 (-0.34%)
Day High
$101.80
Day Low
$101.09
Day Open
$101.60
Prev Close
$101.60
Volume
9,10,872
1W Return
0.13%
1M Return
1.07%
3M Return
0.60%
6M Return
7.64%
1Y Return
89.73%
Market Cap ($ Mn)
6,622
PE Ratio
24.39
PB Ratio
5.01
PEG Ratio
0.22
ROE
20.75%
ROCE
16.84%
EPS (TTM)
$0.34
1 Week
0.13%
1 Month
1.07%
3 Months
0.60%
6 Months
7.64%
9 Months
50.50%
Mizuho cuts Lantheus price target to $109, downgrades to Neutral
Mizuho downgraded Lantheus Holdings from Outperform to Neutral. Price target lowered from $115 to $109. Analyst Anthony Petrone led the rating change.
1mo agoLantheus secures CMS pass-through status for PYLARIFY TruVu from Oct 1
CMS grants Transitional Pass-Through status for PYLARIFY TruVu. Reimbursement separation effective October 1, 2026. Designation supports access for Medicare beneficiaries.
1mo agoLantheus Holdings doses first patient in SPARROW Phase 2/3 trial
First patient dosed in SPARROW NCT07831824, a Phase 2/3 registrational trial. LNTH-2401 targets gastrin-releasing peptide receptor (GRPR) in prostate cancer. Phase 3 segment expects enrollment of approximately 400 participants. Co-primary endpoints are sensitivity and specificity versus histopathology.
1mo agoTwo law firms probe Lantheus Holdings sale to Curium US Holdings
Lantheus Holdings' proposed sale to Curium US Holdings LLC for $102.50 per share in cash is under investigation by two law firms. The deal also includes non-transferable CVRs offering up to $12.00 per share in potential additional payments, subject to commercial milestones through 2030. Kahn Swick & Foti, LLC is assessing whether the offer undervalues Lantheus Holdings and whether the sale process was adequate. Halper Sadeh LLC is separately probing potential federal securities law violations and fiduciary duty breaches, flagging concerns over insider benefits and deal terms that may limit competing offers. Both firms are inviting shareholders to discuss their rights at no cost or obligation.
2mo agoLantheus Holdings Sale to Curium Probed for Fiduciary Breaches
Halper Sadeh LLC probes Lantheus Holdings sale to Curium US for alleged fiduciary breaches. Deal offers $102.50 per share in cash plus up to $12.00 in contingent value rights. Law firm claims insiders may benefit unfairly and competing offers could be limited. Shareholders urged to contact firm for free legal consultation regarding their rights.
2mo agoLantheus secures FDA approval for Alzheimer’s agent TAUKLARIFY
Lantheus Holdings Inc (NASDAQ: LNTH) announced U.S. Food and Drug Administration approval of TAUKLARIFY (florquinitau F 18 injection), also referred to as MK-6240. The radiodiagnostic agent is indicated for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer’s disease to identify patients with tau neurofibrillary tangle pathology. The approval carries a specific limitation of use. The safety and effectiveness of TAUKLARIFY have not been established for the evaluation of non-Alzheimer’s disease tauopathies.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,437.29 | +0.35% | $13,52,123.38M | 39.43 | |
| $280.41 | -0.13% | $6,75,033.80M | 31.06 | |
| $294.98 | +0.37% | $5,21,411.37M | 72.17 | |
| $147.18 | -0.59% | $3,62,834.91M | 117.74 | |
| $160.32 | -1.80% | $3,26,222.34M | 23.23 | |
| $185.48 | -0.69% | $2,87,691.54M | 24.32 | |
| $468.11 | +0.62% | $2,53,205.85M | 26.86 | |
| $169.73 | -0.67% | $2,10,522.74M | - | |
| $29.45 | +0.31% | $1,67,860.70M | 36.79 | |
| $41.09 | +0.96% | $1,39,300.36M | 11.15 | |
| $62.91 | +0.18% | $1,28,593.45M | 14.67 | |
| $48.43 | +0.41% | $1,16,984.89M | 23.63 |
An investment of $100 made 5 years ago in Lantheus Holdings is now worth
$ 337.98
Giving a profit of
$ 237.98 (237.98%)
Note: Past profits do not guarantee future returns.
